Terminated PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT05075577

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

Sponsor: ESSA Pharmaceuticals

Conditions Prostate Cancer

Interventions EPI-7386 with Enzalutamide Enzalutamide

Updated 18 times since 2021 Last updated: Feb 26, 2025 Started: Dec 21, 2021 Primary completion: Oct 31, 2024 Completion: Jan 14, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated early due to a lack of improved efficacy.

Other terminated trials from ESSA Pharmaceuticals

More terminations from ESSA Pharmaceuticals

Other Prostate Cancer trials with similar outcome

Browse all Prostate Cancer trials

This PHASE1/PHASE2 trial investigates Prostate Cancer and is currently terminated or withdrawn. ESSA Pharmaceuticals leads this study, which shows 18 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

18 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Mar 2025 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2

Status: Active Not Recruiting → Terminated
Dec 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 13 earlier versions

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ESSA Pharmaceuticals

Data source: ESSA Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Box Hill, Australia , Buffalo, United States , Calgary, Canada , Camperdown, Australia , Darlinghurst, Australia , Edmonton, Canada , Garran, Australia , Hamilton, Canada , Madison, United States and 10 more locations